Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Sep 8;29(9):6445-6462.
doi: 10.3390/curroncol29090507.

A Review of Current and Emerging Therapies for Advanced Hepatocellular Carcinoma

Angelica Singh  1 , Sofia Zahid  1 , Ilya Noginskiy  1 , Timothy Pak  1 , Soeb Usta  1 , Marina Barsoum  1 , Uqba Khan  1
Affiliations
Review

A Review of Current and Emerging Therapies for Advanced Hepatocellular Carcinoma

Angelica Singh et al. Curr Oncol. .

Abstract

Hepatocellular carcinoma remains a leading cause of cancer-related deaths worldwide. Liver disease including cirrhosis and viral hepatitis remains among the leading causes of hepatocellular carcinoma and despite increased screening, many patients are diagnosed in the advanced stages precluding them from locoregional therapy. Therapeutic agents for advanced hepatocellular carcinoma were limited to Sorafenib for several years; however, with the emergence of molecular targeted therapies including tyrosine kinase inhibitors and vascular endothelial growth factor inhibitors, in addition to immunotherapies, the way hepatocellular carcinoma is treated has changed significantly. In this review, we summarize the key clinical trials that lead to the approval of these agents for systemic treatment of hepatocellular carcinoma and discuss the preferred sequence of treatment options as well as prospective studies for management of hepatocellular carcinoma.

Keywords: combination therapy; hepatocellular carcinoma; immune checkpoint inhibitor; molecular targeted therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Algorithm on how to sequence therapy in patients with advanced hepatocellular carcinoma.
See this image and copyright information in PMC

References

    1. Ryerson A.B., Eheman C.R., Altekruse S.F., Ward J.W., Jemal A., Sherman R.L., Henley S.J., Holtzman D., Lake A., Noone A.-M., et al. Annual Report to the Nation on the Status of Cancer, 1975–2012, Featuring the Increasing Incidence of Liver Cancer: Report on Status of Cancer, 1975–2012. Cancer. 2016;122:1312–1337. doi: 10.1002/cncr.29936. - DOI - PMC - PubMed
    1. Global Burden of Disease Liver Cancer Collaboration. Akinyemiju T., Abera S., Ahmed M., Alam N., Alemayohu M.A., Allen C., Al-Raddadi R., Alvis-Guzman N., Amoako Y., et al. The Burden of Primary Liver Cancer and Underlying Etiologies from 1990 to 2015 at the Global, Regional, and National Level: Results from the Global Burden of Disease Study 2015. JAMA Oncol. 2017;3:1683. doi: 10.1001/jamaoncol.2017.3055. - DOI - PMC - PubMed
    1. Marrero J.A., Kulik L.M., Sirlin C.B., Zhu A.X., Finn R.S., Abecassis M.M., Roberts L.R., Heimbach J.K. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases: Marrero et Al. Hepatology. 2018;68:723–750. doi: 10.1002/hep.29913. - DOI - PubMed
    1. Islami F., Miller K.D., Siegel R.L., Fedewa S.A., Ward E.M., Jemal A. Disparities in Liver Cancer Occurrence in the United States by Race/Ethnicity and State: Liver Cancer in the United States. CA Cancer J. Clin. 2017;67:273–289. doi: 10.3322/caac.21402. - DOI - PubMed
    1. Melkonian S.C., Jim M.A., Reilley B., Erdrich J., Berkowitz Z., Wiggins C.L., Haverkamp D., White M.C. Incidence of Primary Liver Cancer in American Indians and Alaska Natives, US, 1999–2009. Cancer Causes Control. 2018;29:833–844. doi: 10.1007/s10552-018-1059-3. - DOI - PMC - PubMed

MeSH terms